Mounjaro 2.5 mg
  1. Home
  2. Mounjaro
  3. Mounjaro 2.5 mg

Mounjaro 2.5 mg

Mounjaro 2.5 mg is a prescription dual GIP and GLP-1 receptor agonist containing tirzepatide, used to improve glycemic control in adults with type 2 diabetes and, for certain formulations, to support chronic weight management. It is administered as a once-weekly subcutaneous injection using a sterile prefilled injection pen. The 2.5 mg strength is commonly used as the initial treatment dose before gradual dose escalation.

BUY NOW

Category

Mounjaro 2.5 mg contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood glucose and body weight by enhancing glucose-dependent insulin secretion, reducing glucagon release, slowing gastric emptying, and promoting satiety. The 2.5 mg dose is typically prescribed as the starting dose to improve treatment tolerability before increasing to higher doses according to the prescribed treatment plan. Manufactured under stringent pharmaceutical quality standards, the sterile prefilled injection pen is engineered for precise subcutaneous administration and dependable clinical performance. Mounjaro 2.5 mg should be used only under the supervision of a qualified healthcare professional according to the prescribed treatment plan.

Technical Specification

Specification Details
Product Name Mounjaro 2.5 mg
Active Ingredient Tirzepatide
Strength 2.5 mg
Dosage Form Sterile Prefilled Injection Pen
Route of Administration Subcutaneous Injection
Storage Refrigerate at 2°C–8°C before first use

Product Also Known As

Mounjaro 2.5 mg, Tirzepatide 2.5 mg, Mounjaro Injection Pen, Tirzepatide Prefilled Pen, Weekly Tirzepatide Injection, GIP GLP-1 Receptor Agonist, Diabetes Injection Pen